托吡酯相关碳酸饮料味觉异常一例报告
本文报告一例39岁白人女性癫痫患者,在因全面性癫痫发作启动托吡酯治疗后出现碳酸饮料味觉异常,所有碳酸饮料(包括苏打水和啤酒)尝起来「平淡无味」,持续12个月未恢复,Naranjo量表评估提示托吡酯为可能原因。
要点
- 托吡酯可能导致碳酸饮料味觉异常,表现为所有碳酸饮料尝起来平淡无味。
- 该不良反应在用药后立即出现,持续用药12个月未恢复。
- 用吸管饮用碳酸饮料可略微减轻该不良反应。
核心结论
- 托吡酯可能是该患者碳酸饮料味觉异常的原因,Naranjo量表评估为可能。
研究设计与样本
- 个案报告:一例39岁白人女性癫痫患者,因全面性癫痫发作启动托吡酯治疗。
主要发现
- 托吡酯起始剂量为25 mg口服每日两次,3周后滴定至100 mg口服每日两次维持治疗。
- 用药后患者立即出现碳酸饮料味觉改变,所有碳酸饮料包括苏打水和啤酒尝起来「平淡无味」。
- 患者持续用药12个月,味觉异常未恢复正常,用吸管饮用碳酸饮料可略微减轻。
- Naranjo不良反应概率量表评估提示托吡酯为可能原因。
临床怎么用
- 临床应知晓托吡酯可能导致碳酸饮料味觉异常,以便有效咨询患者并提供潜在解决方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A case of carbonation dysgeusia associated with the use of topiramate is reported in order to bring awareness to a lesser-known adverse effect of the medication so that providers may be able to more effectively counsel patients and provide potential solutions. SUMMARY: A 39-year-old Caucasian woman with longstanding epilepsy was initiated on topiramate therapy after experiencing a generalized seizure (she reported not taking any antiepileptic medication for years). Topiramate was started at a dosage of 25 mg by mouth twice daily and after 3 weeks titrated to a dosage of 100 mg by mouth twice daily for maintenance therapy. After initiation of topiramate therapy, the patient began to experience an immediate change in her carbonation perception when drinking carbonated beverages; all carbonated beverages, including seltzer and beer, tasted "flat." The patient remained on topiramate for the subsequent 12 months without her carbonation perception returning to normal but noted that drinking carbonated beverages through straws slightly mitigated the adverse effect. Case assessment using the adverse drug reaction probability scale of Naranjo et al indicated that topiramate was the probable cause of the patient's carbonation taste perversion. CONCLUSION: A 39-year-old Caucasian woman developed chronic carbonation dysgeusia after initiation of topiramate following a generalized seizure.
引用
- Charbonneau M, Doyle-Campbell C, Laskey C, et al. Carbonation dysgeusia associated with topiramate. Am J Health Syst Pharm. 2020. PMID: 32462174. doi:10.1093/ajhp/zxaa123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。